[Rheumatology: 2021 update].
Axel Finckh(University Hospital of Geneva), Kim Lauper(University of Geneva), Michele Iudici, Ilias Lazarou(Center for Rheumatology), Michael J. Nissen(University Hospital of Geneva), Stéphane Genevay(University of Geneva)
Cited by 0
Related Papers
What low back pain is and why we need to pay attention
|The Lancet|2018|4.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Prevention and treatment of low back pain: evidence, challenges, and promising directions
|The Lancet|2018|2.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k